" class="no-js "lang="en-US"> Sohanya Cheng - Medtech Alert
Tuesday, December 03, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Sohanya Cheng

Sohanya Cheng

About Sohanya Cheng

Commercial leader with 10+ years of success in product launches and leading large teams in Oncology, Inflammation, Nephrology, and Bone. Deep experience in Hematology, including leading the commercial launch of the first T cell immunotherapy. Expertise in P&L ownership, developing strategy, leading transformation and organizational design, building and managing large sales and marketing teams, and cross functional leadership.

Related Story

Appointments

 Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer | Pharmtech Focus

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer

January 10 2022

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that […]